Published on 24 Apr 2024 on Investing.com
Arrowhead begins trial for kidney disease treatment By Investing.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR) has initiated a Phase 1/2a clinical trial of...
Want to become a better investor?
Start tracking your investments with Statfolio
Sign up for free